Delving into the Latest Updates on Navivumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

+ [1]

Target

hemagglutinin

Mechanism

hemagglutinin modulators(Influenza virus hemagglutinin glycoproteins modulators)

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Influenza A virus infection

Inactive Indication-

Originator Organization

Celltrion, Inc.

Active Organization

Yonsei University Health System

Centers for Disease Control & Prevention

Inactive Organization

Celltrion, Inc.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 9053374L

Source: *****

Sequence Code 316784540H

Source: *****

There are several broadly neutralizing monoclonal antibodies that neutralize influenza viruses with different mechanisms from traditional polyclonal antibodies induced by vaccination. CT149, which is one of the broadly neutralizing antibodies, was also previously reported to neutralize group 2 and some of group 1 influenza viruses (13 out of 13 tested group 2 viruses and 5 out of 11 group 1 viruses). In this study, we developed another antibody with the aim of compensating partial coverage of CT149 against group 1 influenza viruses. CT120 was screened among different antibody candidates and mixed with CT149. Importantly, although the binding sites of CT120 and CT149 are close to each other, the two antibodies do not interfere. The mixture of CT120 and CT149, which we named as CT-P27, showed broad efficacy by neutralizing 37 viruses from 11 different subtypes, of both group 1 and 2 influenza A viruses. Moreover, CT-P27 showed in vivo therapeutic efficacy, long prophylactic potency, and synergistic effect with oseltamivir in influenza virus-challenged mouse models. Our findings provide a novel therapeutic opportunity for more efficient treatment of influenza.

100 Deals associated with Navivumab

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza A virus infection	Phase 2	-	Centers for Disease Control & Prevention	-
Influenza A virus infection	Phase 2	-	Yonsei University Health System	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03511066 (CTgov)	Phase 2	Influenza A virus infection	228	CT-P27 90 mg/kg (CT-P27 90 mg/kg)	lgmknvklfj(buzocmduvk) = pzstsmlprg iquogdochy (serhdxiwzt, zqvtoikfiq - bkkzcyovbc) View more	-	31 Oct 2022
				CT-P27 45 mg/kg (CT-P27 45mg/kg)	lgmknvklfj(buzocmduvk) = xpjfnrptqs iquogdochy (serhdxiwzt, vumqtnzesb - ysmtvbfnej) View more
NCT02071914 (CTgov)	Phase 2	Influenza A virus infection	81	CT-P27 (CT-P27 10mg/kg)	ixawdawjae(wkwztoxdpq) = ujjzryjsso lmrswazmxn (mozoxeksqj, eofuahsefo - gipdtwsbsa) View more	-	16 Mar 2020
				CT-P27 (CT-P27 20mg/kg)	ixawdawjae(wkwztoxdpq) = vyrbjbcgem lmrswazmxn (mozoxeksqj, nucyfbimti - fqmynqblva) View more